News Releases Year: All News201920182017201620152014 Items per page All News2550 Summary ToggleContraVir Pharmaceuticals’ Cyclophilin Inhibitor, CRV431, Reduces Liver Fibrosis in a Preclinical Model Summary Toggle May 31, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals’ Cyclophilin Inhibitor, CRV431, Reduces Development and Progression of Liver Tumors in Preclinical Hepatocellular Carcinoma Study Summary Toggle May 30, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals to Present at 2018 BIO International Convention Summary Toggle May 29, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals, Inc. Announces Reverse Stock Split Summary Toggle May 24, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals Announces New Data Presented at the 2018 International Liver Congress™ Summary Toggle April 12, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals Appoints Two New Hepatitis B Experts to Scientific Advisory Board Summary Toggle April 9, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals to Present Three Posters at the 53rd Annual International Liver Congress™ Summary Toggle April 3, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals Announces TXL™ Has Been Granted Orphan Drug Designation for the Treatment of HBV in a Pediatric Population Summary Toggle February 22, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until March 9, 2018 Summary Toggle February 21, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals Reaches Agreement with the FDA on the NDA Package for TXL™ Leveraging the 505(b)(2) Regulatory Pathway Summary Toggle February 12, 2018 View News Release > Pagination First page First Previous page Previous … Page 2 Current page 3 Page 4 Page 5 … Next page Next Last page Last
